GLP-2T is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It activates both incretin receptors simultaneously, modulating insulin secretion, glucagon levels, and gastric emptying through central signaling pathways. In a comparative research context, GLP-2T is referenced as a structural analog of tirzepatide — the dual-agonist compound described in the published SURPASS/SURMOUNT trial literature — and is supplied solely as a reference research compound for in-vitro laboratory study. It is not tirzepatide, not an approved drug, and not a substitute for any approved medication. For research purposes only.

Research Observations

• Dual incretin receptor activation studied in clinical trials
• Glycemic modulation observed in type 2 diabetes research models
• Glucose pathway and insulin signaling studied in preclinical settings
• Cardiovascular risk factor observations reported in clinical studies
• Central signaling pathway modulation studied in vitro